{
  "id": 16026875,
  "title": "Rakovina Therapeutics and Variational AI Advance Brain-Penetrant ATR Program Toward Development Candidate Selection",
  "url": "https://urgent.news/2026/10/22/rakovina-therapeutics-and-variational-ai-advance-brain-penetrant-atr",
  "topic": "ai",
  "section": "AI",
  "published": "2026-10-22T09:34:41.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/rakovina-therapeutics-and-variational-ai-advance-brain-penetrant-atr-program-toward-development-candidate-selection"
  },
  "original_language": "en",
  "account": null,
  "summary": "kt-5000AI delivers potent and selective ATR inhibition, CNS-oriented properties and preclinical tumour-growth control, advancing a capital-efficient drug discovery program toward candidate selection VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}